Pre-planned secondary analysis of a trial in advanced cancer with agitated end-of-life delirium (67 patients): caregiver-defined sedation goals at 24 h were met with lorazepam 76.9%, combination 61.5%, placebo 53.8% and haloperidol 21.4% (P=0.02).
Secondary analysisn = 67
Huang et al. Personalized Sedation Goals for Agitated End-of-Life Delirium: Secondary Analysis of RECORD Trial